TAK-659 and Paclitaxel in Treating Patients With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 5, 2019

Primary Completion Date

February 23, 2023

Study Completion Date

February 23, 2023

Conditions

Advanced Malignant Solid NeoplasmOvarian CarcinomaRefractory Malignant Solid NeoplasmRefractory Ovarian Carcinoma

Interventions

DRUG

Mivavotinib

Given PO

DRUG

Paclitaxel

Given IV

OTHER

Pharmacokinetic Study

Correlative studies

Trial Locations (1)

M D Anderson Cancer Center, Houston

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT03756818 - TAK-659 and Paclitaxel in Treating Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter